Business Context and Reporting Period
Company: Autonomix Medical, Inc. (AMIX)
Filing Type: Form 8-K (Current Report)
Date of Report: August 25, 2025
Reporting Period: Event date August 25, 2025; Signed August 27, 2025
The Company is an emerging growth company incorporated in Delaware. This filing reports an amendment to an existing At Market Issuance Sales Agreement.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The filing focuses exclusively on capital structure adjustments.
- Capital Raise Mechanism: At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc.
- Original Aggregate Sales Price: $2.1 million (established July 26, 2024).
- Amendment Amount: $1.4 million increase.
- New Aggregate Sales Price: $3.5 million (implied total capacity).
Material Changes
On August 25, 2025, the Company increased the aggregate sales price of shares available for sale under its existing Sales Agreement by $1.4 million. This action expands the Company's ability to raise capital through the sale of common stock via the agent.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the execution of the amendment to the Sales Agreement to increase available capital. No specific operational guidance or forward-looking financial projections are provided in this document.
Risks and Contingencies: The filing notes that any sale of shares will be made under the Company's effective "shelf" registration statement on Form S-3 (File No. 333-285464), which became effective on March 11, 2025. The Company has elected to use the extended transition period for complying with new or revised financial accounting standards as an emerging growth company.
Investor Verification Checklist
- Verify the total number of shares previously sold under the original $2.1 million agreement to determine the remaining capacity.
- Review the effective Form S-3 registration statement (File No. 333-285464) for updated prospectus supplements.
- Monitor future 8-K filings for actual sales transactions executed under the amended agreement.
- Confirm the Company's current cash position in the most recent 10-Q or 10-K to assess the necessity of this capital raise.